Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany defends AstraZeneca pivot as key to speeding vaccinations

Fri, 07th May 2021 09:54

* All adults now free to get AZ shot, on doctor's advice

* Gap between doses can be as little as 4 weeks

* Experts warn on reduced efficacy with shorter gap

* Third wave of pandemic "appears to be broken" - minister
(Recasts to lead on AstraZeneca shift)

By Douglas Busvine and Paul Carrel

BERLIN, May 7 (Reuters) - Health Minister Jens Spahn on
Friday defended another U-turn by Germany on the AstraZeneca
vaccine, saying making it available to all adults who
want it would protect more people against COVID-19 more quickly.

Spahn announced late on Thursday that Germany would make
AstraZeneca available to all adults, subject to consulting a
doctor, and allow people to get a second shot as soon as four
weeks after the first.

The move comes with an eye to the summer holidays and
coincides with the rapid passage of legislation that would free
those fully vaccinated from social distancing measures imposed
to fight the pandemic.

Germany had previously limited the shot from the
Anglo-Swedish drugmaker to people over 60 after post-vaccination
monitoring found rare - and sometimes fatal - cases of blood
clotting, with younger women disproportionately affected.

Before that, its vaccine oversight body had said the shot
could not be given to the elderly because of a lack of data from
clinical trials.

With 70% of older people now inoculated and Germany's
vaccination drive gaining momentum, Spahn said the latest step
on AstraZeneca would offer a vaccination option to people who
would otherwise have to wait.

"We are convinced this offer is attractive for those who
would otherwise not get vaccinated so quickly," Spahn told a
news conference, adding that 1 million AstraZeneca doses would
be sent to doctors' practices next week.

THE SOONER, THE WORSE?

The decision by the federal government follows moves by
several German states to make AstraZeneca more widely available
and comes as the pace of giving shots of mainstay vaccines from
BioNTech/Pfizer and Moderna picks up.

The share of the population that has received a first
vaccine shot has reached 31.5%, with 900,000 getting a dose on
Thursday, putting Germany "in the fast lane" by international
standards, said Spahn.

He said the third wave of the coronavirus pandemic "appears
to be broken" while Germany's top public health official, Lothar
Wieler, said infections were falling across all age groups
thanks to social distancing and the progress on vaccinations.

Confirmed cases rose by 18,485 on Friday, with 284
fatalities, while the seven-day incidence fell to 125.7 cases
per 100,000 people, data from the Robert Koch Institute showed.

However, experts criticised the decision to allow people to
receive the AstraZeneca vaccine at shorter intervals, saying
studies had shown its efficacy to be only around 55% with a
four-week gap and 80% with a 12-week delay to the second shot.

"We have to make it clear that if people shorten the gap
between AstraZeneca doses to enjoy greater freedom of movement
sooner, they are doing so at the cost of their immune
protection," said Carsten Watzl, professor of immunology at the
Dortmund Technical University.

Spahn said this was a decision that people should take with
proper advice, a view seconded by Robert Koch Institute head
Wieler.

"We know that the longer the gap before the second shot the
better the protection," Wieler said. "This is an informed
decision people can take in consultation with their doctors."
(Writing by Douglas Busvine
Editing by Gareth Jones)

More News
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.